NATIONAL JEWISH HEALTH
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1899-01-01
- Employees
- -
- Market Cap
- -
Clinical Trials
110
Trial Phases
5 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (48 trials with phase data)• Click on a phase to view related trials
Effect of Omalizumab in the Skin of Food Allergy Patients
- Conditions
- Food AllergyFood Allergy in Children
- Interventions
- First Posted Date
- 2024-10-01
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- National Jewish Health
- Target Recruit Count
- 40
- Registration Number
- NCT06618963
- Locations
- 🇺🇸
National Jewish Health, Denver, Colorado, United States
Enhancing Hypnotic Medication Discontinuation in Primary Care
- Conditions
- InsomniaHypnotic Dependence
- First Posted Date
- 2024-05-30
- Last Posted Date
- 2025-06-06
- Lead Sponsor
- National Jewish Health
- Target Recruit Count
- 430
- Registration Number
- NCT06435520
- Locations
- 🇺🇸
National Jewish Health, Denver, Colorado, United States
Nasal Inflammation Following Endotoxin Challenge in Patients With Asthma
- Conditions
- Asthma; EosinophilicAsthma
- Interventions
- Drug: Lipopolysaccharides
- First Posted Date
- 2024-02-21
- Last Posted Date
- 2024-02-21
- Lead Sponsor
- National Jewish Health
- Target Recruit Count
- 60
- Registration Number
- NCT06270576
- Locations
- 🇺🇸
National Jewish Health, Denver, Colorado, United States
Mycobacteriophage Treatment of Non-tuberculosis Mycobacteria
- Conditions
- Cystic FibrosisNontuberculous Mycobacterium InfectionMycobacterium InfectionsMycobacterium; PulmonaryNontuberculous Mycobacterial Lung Disease
- Interventions
- Biological: mycobacteriophage
- First Posted Date
- 2024-02-16
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- National Jewish Health
- Target Recruit Count
- 10
- Registration Number
- NCT06262282
- Locations
- 🇺🇸
University of Alabama, Birmingham, Alabama, United States
🇺🇸Children's Hospital of Los Angeles, Los Angeles, California, United States
🇺🇸University of California, San Diego, California, United States
Transmission and Acquisition of Nontuberculous Mycobacteria Outbreak Investigation (TrANsMIt)
- Conditions
- Nontuberculous Mycobacterial Pulmonary InfectionMycobacterium InfectionsOutbreak InvestigationHealthcare Associated Infection
- First Posted Date
- 2023-12-04
- Last Posted Date
- 2023-12-12
- Lead Sponsor
- National Jewish Health
- Target Recruit Count
- 100
- Registration Number
- NCT06155747
- Locations
- 🇺🇸
National Jewish Health, Denver, Colorado, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 22
- Next
News
Clarametyx's CMTX-101 Shows Promise in Cystic Fibrosis Infection Trial, Advances to Next Phase
Clarametyx Biosciences announced positive interim results from its Phase 1b/2a trial of CMTX-101, an immune-enabling antibody therapy for cystic fibrosis-associated pulmonary infections.
Tezepelumab Shows 79% Reduction in Severe Asthma Exacerbations in Real-World Study
Phase 4 PASSAGE study demonstrates tezepelumab reduced annualized asthma exacerbation rates by 79% in real-world patients with severe asthma after 6 months of treatment.